ClinicalTrials.gg
CompletedNCT06599684Updated Oct 2, 2026

Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

A Phase 2 interventional study of INV-102 in Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy and Diabetic Retinopathy, sponsored by Invirsa, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Invirsa, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Enrollment
159th of 196
19 · median 72
Started
2024
with 10 others
Phase 2
52 of 267
3 open now
Registered
233rd of 267
by date

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 159th largest by enrollment of the 196 interventional ones that give a count, is one of 11 that started in 2024, is one of 52 in phase 2, and was the 233rd registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period in subjects with center-involved DME (CIDME) associated with NPDR [Part 2].

03

Conditions studied

  • Non-center Involved Diabetic Macular Edema
  • Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
  • Diabetic Retinopathy
  • Center-involved Diabetic Macular Edema
  • Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female subjects ≥ 18 years of age and \< 76 years of age
  • Diagnosed with diabetes (Type 1 or 2) with ≤ 12.0%
  • Study eye must have NCIDME (Part 1) or CIDME (Part 2)
  • Study eye must be moderate to severe NPDR

Key Exclusion Criteria:

  • Prior laser treatment for DR in the study eye within 12 months from Screening Visit
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Part 1: INV-102 0.7% in NCIDME

    INV-102 0.7% Ophthalmic Solution given three times daily (TID) for 2 weeks followed by twice daily (BID) for 10 weeks

    Drug: INV-102

  • Experimental
    Part 2: INV-102 0.7% in CIDME

    INV-102 0.7% Ophthalmic Solution given three times daily (TID) for 2 weeks followed by twice daily (BID) for 6 weeks

    Drug: INV-102

Interventions

  • 0.7% Ophthalmic Solution

06

What researchers measure

Primary outcomes

  1. Change from baseline in the Early Treatment Diabetic Retinopathy (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) score

    Graded by an independent central reading center using Wide-field Color Fundus Photography. The DRSS divides diabetic retinopathy into levels ranging from absence of retinopathy (score = 10) to advanced retinopathy (score = 85). The scale is used to describe overall retinopathy severity as well as the change in severity over time.

    Time frame: Day 84 (Part 1) and Day 56 (Part 2)

  2. Change from baseline in central subfield thickness (Part 2 only)

    Measured using spectral domain optical coherence tomography (SD-OCT) and determined by an independent central reading center.

    Time frame: Day 56

Secondary outcomes

  1. Change from baseline in macular volume

    Measured using spectral domain optical coherence tomography (SD-OCT)

    Time frame: Day 84 (Part 1) and Day 56 (Part 2)

  2. Change from baseline in subfield thickness

    Mean retinal thickness in each of the regional subfields of the ETDRS grid, measured using SD-OCT

    Time frame: Day 84 (Part 1) and Day 56 (Part 2)

  3. Change from baseline in the retinal thickness at the thickest point of the subfield thickness

    Measured using SD-OCT in each of the regional subfields of the ETDRS grid

    Time frame: Day 84 (Part 1) and Day 56 (Part 2)

  4. Change in best corrected visual acuity (BCVA) (Part 2 only)

    Time frame: Day 56

07

Study locations

1 site
  • MedTrials, Inc.
    Dallas, Texas 75204, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Sep 2025, 12 months.

Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's 12 months is below that.

Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2024
First posted
Sep 19, 2024
StartActual
Sep 7, 2024
Primary completionActual
Sep 30, 2025
CompletionActual
Sep 30, 2025
Results delay requested
Sep 29, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: registry dates
1 update, last Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Minor edits only
    + 1 other change: registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06599684
Lead sponsor
Invirsa, Inc.
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 7, 2024
Primary completion
Sep 30, 2025
Completion
Sep 30, 2025
Last update
Oct 2, 2026

Study contacts

Robert Shalwitz
study chair · Invirsa, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: INV-102

Start the discussion